Improvement in the Survival of Esophageal Cancer Patients at Cancer Institute of Iran after Implementation of the Neo-adjuvant Chemo-radiation: Retrospective Cohort Study

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 57

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MISJ-12-4_010

تاریخ نمایه سازی: 25 آبان 1402

Abstract:

Background: Iran is a high-risk area with a poor prognosis for esophageal cancer. We conducted the present study to evaluate the survival rate of esophageal cancer after the introduction of neo-adjuvant chemo-radiation at the Cancer Institute of Iran. Method: We performed a retrospective cohort study and abstracted the data of ۴۲۱ patients who referred to the Cancer Institute of Iran between ۲۰۰۷ and ۲۰۱۱. Life table and Kaplan-Meier approaches were applied to estimate ۱-, ۳-, and ۵-year survival rates and corresponding ۹۵% confidence intervals (CI). Multiple Cox regression model was recruited for investigating the association between ۵-year survival rate and prognostic factors. Results: We found that ۱-, ۳-, and ۵-year survival rates were ۶۶.۷%, ۲۸.۲, and ۲۰.۹%, respectively. The hazard ratio (HR) was significantly higher among the patients who has received definitive chemo-radiation therapy (Hazard ratio (HR) = ۲.۲, ۹۵% confidence interval (CI): ۱.۱, ۴.۲), surgery (HR= ۲.۰ ۹۵% CI: ۱.۰, ۳.۷), and palliative care (HR= ۴.۲, ۹۵% CI: ۲.۱, ۱.۸) compared with those who received neo-adjuvant chemo-radiation and surgery. We also found that the ۵-year survival rate was doubled in the current study conducted between ۲۰۰۷ and ۲۰۱۱ (۲۰.۹%) compared with the previous one conducted between ۱۹۹۷ and ۲۰۰۶ (۱۰.۰%). Additionally, a considerable improvement was observed in ۱- and ۳-year survival rate of esophageal cancer at the Cancer Institute of Iran. Conclusion: Following the administration of neo-adjuvant chemo-radiation therapy, the prognosis of esophageal cancer has improved significantly at the Cancer Institute of Iran during the last decade. More data from other cancer centers and provinces of Iran are required.

Authors

Saeed Nemati

Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran

Maryam Hadji

Faculty of Social Sciences, Tampere University, Tampere, Finland

Parissa Seifi

Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran

Mohammad Shirkhoda

Department of Surgery, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran

Mojtaba Vand Rajabpour

Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran

Nazanin Rajaei

Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran

Mahdi Aghili

Radiation Oncology Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran

Mohammad Ali Mohagheghi

Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran

Kazem Zendehdel

Cancer Biology Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran